It covers the computational systems that we built to design and test a new family of chemical compounds in silico, synthesis of several prototypes, all the way through preliminary in vivo testing. It’s the culmination of about 4 yrs of work starting at SENS, finished at Underdog and involving collaborations with leading experts in Spain, Hungary, and China. Give it a look and let us know what you think!
We are excited to share that Cyclarity revealed Phase 1 clinical trial results for UDP-003 last night, presented at the American Heart Association Vascular Discovery Scientific Sessions by our VP of Biology, Daniel Clemens.
Johan van Wyck, Resident Director of Cyclarity Therapeutics Australia Pty Ltd, represented Cyclarity on the clinical panel at AusBiotech 2025. He discussed the clinical progress of Cyclarity’s UDP-003 and explained why Australia was chosen as the strategic location for conducting Phase 1 trials
Cyclarity Therapeutics, Inc. today announced its newly formed Clinical Advisory Board to guide its clinical development of drug candidate UDP-003 for the treatment and prevention of atherosclerosis, primary coronary artery disease, and associated cardiovascular diseases.
Cyclarity Therapeutics, Inc. today announced its newly formed Clinical Advisory Board to guide its clinical development of drug candidate UDP-003 for the treatment and prevention of atherosclerosis, primary coronary artery disease, and associated cardiovascular diseases.
Cyclarity Therapeutics, Inc. is proud to present a one-sheet summarizing our approach to curing heart disease, the results we’ve achieved thus far, and the status of our ongoing efforts.
Cyclarity Therapeutics, Inc. today announced its newly formed Clinical Advisory Board to guide its clinical development of drug candidate UDP-003 for the treatment and prevention of atherosclerosis, primary coronary artery disease, and associated cardiovascular diseases.
Cyclarity Therapeutics, Inc. today announced its newly formed Clinical Advisory Board to guide its clinical development of drug candidate UDP-003 for the treatment and prevention of atherosclerosis, primary coronary artery disease, and associated cardiovascular diseases.
Pre-proofs are now available for our latest manuscript in Carbohydrate Polymers: “Addressing the complexities in measuring cyclodextrin-sterol binding constants: A multidimensional study”.
Watch Cyclarity CEO of Scientific Affairs Dr. Oki O’Connor talk with Phil Newman of Longevity.Technology about Cyclarity’s elegant solution to one of the world’s biggest problems – atherosclerosis.
Congratulations to our diligent and talented team members who are taking on larger roles as we develop our novel technologies to cure atherosclerosis!
We invite you to read the Longevity.Technology report “Disease management to disease modification – removing plaque to undo atherosclerosis”.
Watch Cyclarity CEO of Corporate Affairs Mike Kope talk with Phil Newman of Longevity.Technology about tackling oxidized cholesterol and taking on the world’s biggest killer.